The upregulation of SGLT-2 in patients with T2D is associated with important metabolic and hemodynamic consequences because multiple therapeutic benefits are produced by SGLT-2 inhibition [95]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.